Volume 9, Issue 4 (Vol.9 No.4 Jan 2021)                   rbmb.net 2021, 9(4): 379-384 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shapouri-Moghaddam A, Tavakkol Afshari S J, Rahimi H R, Saeed Modaghegh M, Mahmoudi M, Ehteshamfar S M. Para-Clinical and Immunological Evaluation in Buerger's Disease as a Suspected Autoimmune Disease: Case Series. rbmb.net. 2021; 9 (4) :379-384
URL: http://rbmb.net/article-1-558-en.html
Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:   (1077 Views)
Background: Autoimmunity causes the loss of normal immune homeostasis and involves the presence of autoantibodies and inflammation. Thromboangiitis obliterans or Buerger's disease (BD) refers to a type of vascular obstructive syndrome, with tobacco exposure accounting for disease formation and progression. However, the current understanding of autoimmunity is unclear in the context of BD, and the scientific findings are not enough to support autoimmune mechanisms. This study was aimed at investigating autoimmunity factors in patients with BD.

Methods: Clinical and experimental examinations were performed on 80 patients with BD. The diagnostic work-up for autoimmunity was composed of IgM rheumatoid factor (RF), anti-nuclear antibodies (ANA), The erythrocyte sedimentation rate (ESR), anti-cyclic citrullinated peptide (CCP) antibodies, Antiphospholipid antibodies (APA), Anti-cardiolipin antibodies (ACLA), anti-double-stranded DNA (ds-DNA), and extractable nuclear antigen (ENA) profile. Immunomarkers were detected using the quantitative enzyme-linked immunosorbent assay (ELISA).

Results: Raynaud's phenomenon (84.93%), cold sensitivity (76.25%), and claudication (73.75%) were the most common symptoms in the BD patients. Also, 64.29% represented with high ANA levels and positive RF, while 42.11% were found with increased ANA and ESR levels. The ANA/RF positive BD patients had ESR> 15 mm/hr and a high prevalence of cold sensitivity, claudication, and Raynaud's phenomenon (p> 0.05).

Conclusions: There is a possibility of a non-specific autoimmune disposition among BD patients. RF and ANA could be considered for predicting disease progression.
Full-Text [PDF 215 kb]   (250 Downloads)    
Type of Article: Original Article | Subject: Immunology
Received: 2020/08/31 | Accepted: 2020/09/10 | Published: 2021/03/8

References
1. Klein-Weigel P, Volz T, Gutsche-Petrak B, Boehnlein J, Bohlen A. Immunoadsorption in Buerger'S Disease (Thromboangiitis Obliterans): A Promising Therapeutic Option: Results of a Consecutive Patient Cohort Treated in Clinical Routine Care. Lupus Open Access. 2016;1(114):2. [DOI:10.35248/2684-1630.16.1.114]
2. Narváez J, García-Gómez C, Álvarez L, Santo P, Aparicio M, Pascual M, et al. Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature. Medicine (Baltimore). 2016;95(48):e5511. [DOI:10.1097/MD.0000000000005511] [PMID] [PMCID]
3. Rivera-Chavarría IJ, Brenes-Gutiérrez JD. Thromboangiitis obliterans (Buerger's disease). Ann Med Surg (Lond). 2016;7:79-82. [DOI:10.1016/j.amsu.2016.03.028] [PMID] [PMCID]
4. Jiménez-Ruiz C, Dale L, Mochales JA, Buendía LV, de Granda Orive I, García AG. Smoking characteristics and cessation in patients with thromboangiitis obliterans. Monaldi Arch Chest Dis. 2016;65(4):217-21. [DOI:10.4081/monaldi.2006.552] [PMID]
5. Igari K, Inoue Y, Iwai T. The epidemiologic and clinical findings of patients with Buerger disease. Ann Vasc Surg. 2016;30:263-9. [DOI:10.1016/j.avsg.2015.07.014] [PMID]
6. Higashi Y, Azuma N, Takeishi Y, Minamino T, Kihara Y, Node K, et al. Effect of a Low-Intensity Pulsed Ultrasound Device, SX-1001, on Clinical Symptoms in Buerger Disease with Limb Ischemia. Int Heart J. 2015;56(6):632-8. [DOI:10.1536/ihj.15-191]
7. De JH, Florez A, Fernandez JL, Acin F. Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report. BMJ Case Reports. 2009;2009. [DOI:10.1136/bcr.08.2008.0691] [PMID] [PMCID]
8. Decousus H, Quéré I, Presles E, Becker F, Barrellier M-T, Chanut M, et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med. 2010;152(4):218-24. [DOI:10.7326/0003-4819-152-4-201002160-00006] [PMID]
9. Del Conde I, Peña C. Buerger disease (thromboangiitis obliterans). Tech Vasc Interv Radiol. 2014;17(4):234-40. [DOI:10.1053/j.tvir.2014.11.003] [PMID]
10. Vijayakumar A, Tiwari R, Kumar Prabhuswamy V. Thromboangiitis obliterans (Buerger's disease)-current practices. Int J Inflam. 2013;2013:156905. [DOI:10.1155/2013/156905] [PMID] [PMCID]
11. Quintero OL, Rojas-Villarraga A, Mantilla RD, Anaya J-M. Autoimmune diseases in the intensive care unit. An update. Autoimmun Rev. 2013;12(3):380-95. [DOI:10.1016/j.autrev.2012.06.002] [PMID]
12. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010;34(3):J258-65. [DOI:10.1016/j.jaut.2009.12.003] [PMID]
13. Smolen JS, Youngchaiyud U, Weidinger P, Kojer M, Endler AT, Mayr WR, et al. Autoimmunological aspects of thromboangiitis obliterans (Buerger's disease). Clinical immunology and immunopathology. 1978;11(2):168-177. [DOI:10.1016/0090-1229(78)90041-7]
14. Hassoun Z, Lacrosse M, De Ronde T. Intestinal involvement in Buerger's disease. Journal of clinical gastroenterology. 2001;32(1):85-9. [DOI:10.1097/00004836-200101000-00020] [PMID]
15. Sasaki S, Sakuma M, Kunihara T, Yasuda K. Distribution of arterial involvement in thromboangiitis obliterans (Buerger's disease): results of a study conducted by the Intractable Vasculitis Syndromes Research Group in Japan. Surg today. 2000;30(7):600-5. [DOI:10.1007/s005950070099] [PMID]
16. Asouri M, Alinejad Rokni H, Sahraian MA, Fattahi S, Motamed N, Doosti R, et al. Association of HLA-DRA and IL2RA Polymorphisms with the Severity and Relapses Rate of Multiple Sclerosis in an Iranian Population. rbmb. 2020;9(2):129-139. [DOI:10.29252/rbmb.9.2.129] [PMID] [PMCID]
17. Kopan R, Ilagan MXG. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137(2):216-33. [DOI:10.1016/j.cell.2009.03.045] [PMID] [PMCID]
18. Shapouri-Moghaddam A, Mohammadi M, Rahimi HR, Esmaeili H, Mahmoudi M, Modaghegh M-HS, et al. The Association of HLA-A, B and DRB1 with Buerger's Disease. Rep Biochem Mol Biol. 2019;8(2):153-160.
19. Dargon PT, Landry GJ. Buerger's disease. Ann Vasc Surg. 2012;26(6):871-80. [DOI:10.1016/j.avsg.2011.11.005] [PMID]
20. Malik S, Bruner GR, Williams-Weese C, Feo L, Scofield RH, Reichlin M, et al. Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients. Lupus. 2007;16(11):863-6. [DOI:10.1177/0961203307083365] [PMID]
21. Ehteshamfar SM, Afshari JT, Modaghegh MS, Mahmoudi M, Kazemzadeh GH, Kermani FS. Humoral and cellular immune response to Buerger's disease. Vascular. 2020;28(4):457-464. [DOI:10.1177/1708538120910055] [PMID]
22. Fritzler MJ. The antinuclear antibody test: last or lasting gasp?. Arthritis Rheum. 2011;63(1):19-22. [DOI:10.1002/art.30078] [PMID]
23. Syed RH, Gilliam BE, Moore TL. Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology. Curr Rheumatol Rep. 2008;10(2):156-63. [DOI:10.1007/s11926-008-0027-4] [PMID]
24. Moore TL, Dalrymple AM. Laboratory Studies in Autoimmune Diseases. Mo Med. 2016;113(2):118-122.
25. Harrison M. Erythrocyte sedimentation rate and C-reactive protein. Aust Prescr. 2015;38(3):93-94. [DOI:10.18773/austprescr.2015.034] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb